SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
SELB
--
0.00%
--
Selecta Biosciences (SELB) Investor Presentation - Slideshow
Seeking Alpha - Article · 3d ago
Is Selecta (SELB) Stock a Solid Choice Right Now?
Selecta (SELB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks · 05/29 12:52
Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference
Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D.
GlobeNewswire · 05/26 12:00
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Selecta Biosciences, Inc. - SELB
New York, New York--(Newsfile Corp. - May 20, 2020) -  Levi & Korsinsky announces it has commenced an investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.
Newsfile · 05/20 17:06
2 Strong Buy Penny Stocks With Blockbuster Potential
TipRanks · 05/18 15:04
Shareholder Alert: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Selecta Biosciences, Inc. - SELB
Newsfile · 05/12 17:49
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 17:07
Selecta Biosciences, Inc. (SELB) Q1 2020 Earnings Call Transcript
Joining me today is Carsten Brunn, our President and Chief Executive Officer; and Brad Dahms, our Chief Financial Officer. In addition, Kei Kishimoto, our Chief Scientific Officer, will be available for the Q&A portion of the call.
Motley Fool · 05/08 18:30
Selecta Biosciences EPS beats by $0.07
Selecta Biosciences (NASDAQ:SELB): Q1 GAAP EPS of -$0.21 beats by $0.07. Cash and cash equivalents of $72.6M Press Release
seekingalpha · 05/07 16:35
Selecta Biosciences Q1 EPS $(0.210) Beats $(0.280) Estimate
Selecta Biosciences (NASDAQ:SELB) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.280) by 25 percent. This is a 32.26 percent increase over losses of $(0.310) per share
Benzinga · 05/07 11:56
Selecta Biosciences Reports First Quarter 2020 Financial Results
- Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 - - Phase 3 clinical program of SEL-212 to commence in 2H.
GlobeNewswire · 05/07 11:30
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Selecta Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Selecta Biosciences, Inc. (NASDAQ: SELB).
PR Newswire · 05/06 16:04
Selecta Biosciences to Present at the Bank of America Merrill Lynch 2020 Health Care Conference
Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D.
GlobeNewswire · 05/05 12:00
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Recent Operational Highlights
Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that it plans to host a conference call on Thursday, May 07,
GlobeNewswire · 04/30 12:00
Selecta Biosciences Appoints Dr. Goran Ando to its Board of Directors
Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Dr. Goran Ando to its Board of Directors,
GlobeNewswire · 04/28 12:00
Selecta Biosciences (SELB) Investor Presentation - Slideshow
Seeking Alpha - Article · 04/15 19:59
Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
GlobeNewswire · 04/07 13:00
Edited Transcript of SELB earnings conference call or presentation 12-Mar-20 12:30pm GMT
Thomson Reuters StreetEvents · 03/30 19:03
RDS.A, NRZ among premarket gainers
Seeking Alpha - Article · 03/19 13:20
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2019 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 03/12 17:42